Thryv Therapeutics is a clinical-stage biotechnology company developing potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision therapies for cardiovascular diseases, including congenital Long QT Syndrome, heart failure with reduced ejection fraction and atrial fibrillation. Its lead candidate THRV-1268 is being evaluated in the Wave II Phase 2/3 study in Long QT Syndrome Types 2 and 3, which holds an FDA Fast Track designation, and in ASPIRE-HF, a Phase 2a study in heart failure. Formerly known as LQT Therapeutics, the company is headquartered in Montreal, Quebec.
1
Round
1
Industry
5
Tags
Nov 3, 2026
Latest raise
Funding activity · 1 round
Nov 3, 2026
$30M
Series B
Led by InClin, Inc.
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
